Cartesian Therapeutics, Inc.
- RNAC
- NASDAQ
- Biotechnology
- mRNA Cell Therapies
- CAR-T for Autoimmune Diseases
$6.08
Today −3.03%Quote Oct 19, 2026, 08:00 PM UTC
−24.28%over the last month
Max drawdown −24.8%From 1-month high −24.8%3 months −25.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
75
Market value
$184.0M
Quote Oct 19
Analyst target
$25.00
+311.2% from here
Floor
$6.04
0.7% below price
Resistance
$6.56
7.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RNACPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free